对支气管哮喘特异性免疫治疗的再认识  

Further understanding of specific immunotherapy in bronchial asthma

作　　者：俞绮虹[1] 林燕萍[1] 

机构地区：[1]天津市胸科医院呼吸内科,300051

出　　处：《中华哮喘杂志（电子版）》2012年第1期51-54,共4页Chinese Journal of Asthma(Electronic Version)

摘　　要：支气管哮喘(简称哮喘)的药物治疗如吸入性糖皮质激素可以提供有效的抗炎作用,但是不能治愈哮喘或改变疾病的自然病程。变应原特异性免疫治疗针对哮喘的内在免疫机制,包括Th2细胞的病理性激活,因此对于特应性个体同时出现的各种变应性疾病都可以起到治疗作用,并且可能改变变应性疾病的自然过程。舌下免疫治疗对变应性鼻炎和哮喘具有与皮下注射免疫治疗相似的临床疗效,同时比皮下注射免疫治疗更安全、便捷。已经出现了一些免疫治疗的新方法,希望新的方法更加成熟、有效,使免疫治疗成为哮喘治疗的重要方法。Current pharmacotherapy, such as inhaled corticosteroids （ICS）, provides powerful anti-symptomatic benefits in bronchial asthma （asthma）. However, it does not cure or modify the natural course of allergic disease. Immunotherapy targets the immunological background in asthma, including pathological activation of Th2 cells, thus providing therapeutic potency for the variety of allergic diseases observed simultaneously in allergic individuals, and possibly modifying the natural course of allergic diseases.Subcutaneous immunotherapy （SLIT） has been shown to be as effective for allergic rhinitis and asthma as SCIT, and SLIT is more safer and convenient. New forms of immunotherapy are also being developed. It is hoped that the novel approaches will become more sophisticated and provide better efficacy,thus making immunotherapy more important therapy for asthma.

关 键 词：支气管哮喘 变应性 特异性免疫治疗 

分 类 号：R725.622.5[医药卫生—儿科]